{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:36:18Z","timestamp":1768325778442,"version":"3.49.0"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010753","name":"National Health Laboratory Service","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010753","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0234937","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T19:16:38Z","timestamp":1592507798000},"page":"e0234937","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7541-8132","authenticated-orcid":true,"given":"Adriaan E.","family":"Basson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salome","family":"Charalambous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3961-7828","authenticated-orcid":true,"given":"Lynn","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"issue":"9534","key":"pone.0234937.ref001","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0140-6736(06)69162-9","article-title":"The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic","volume":"368","author":"JS Montaner","year":"2006","journal-title":"Lancet (London, England)"},{"key":"pone.0234937.ref002","unstructured":"UNAIDS. UNAIDS 2018 Reference. UNAIDS\/JC2929E. 2018."},{"key":"pone.0234937.ref003","unstructured":"UNAIDS. UNAIDS \u2018AIDSinfo\u2019. UNAIDS \"AIDSinfo'. 2018."},{"key":"pone.0234937.ref004","unstructured":"NDOH. National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV (pMTCT) and the Management of HIV in Children, Adolescents and Adults. 2015."},{"issue":"1","key":"pone.0234937.ref005","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jac\/dkw358","article-title":"HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa","volume":"72","author":"K Steegen","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"pone.0234937.ref006","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/tmi.12563","article-title":"Virological efficacy with first-line antiretroviral treatment in India: predictors of viral failure and evidence of viral resuppression","volume":"20","author":"A Shet","year":"2015","journal-title":"Trop Med Int Health"},{"issue":"7","key":"pone.0234937.ref007","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/cid\/cit933","article-title":"High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy","volume":"58","author":"RK Gupta","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0234937.ref008","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31829f05ac","article-title":"Viral load monitoring as a tool to reinforce adherence: a systematic review","volume":"64","author":"K Bonner","year":"2013","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"issue":"3","key":"pone.0234937.ref009","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/QAI.0b013e318266ee3f","article-title":"Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program","volume":"61","author":"V Johnston","year":"2012","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"issue":"2","key":"pone.0234937.ref010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2010","article-title":"Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients","volume":"17","author":"RE Barth","year":"2012","journal-title":"Antiviral therapy"},{"issue":"117","key":"pone.0234937.ref011","article-title":"Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa","volume":"2","author":"Z El-Khatib","year":"2011","journal-title":"Journal of AIDS & clinical research"},{"key":"pone.0234937.ref012","doi-asserted-by":"crossref","first-page":"469127","DOI":"10.1155\/2011\/469127","article-title":"Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy","volume":"2011","author":"C Orrell","year":"2011","journal-title":"AIDS research and treatment"},{"issue":"12","key":"pone.0234937.ref013","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1086\/648444","article-title":"Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa","volume":"49","author":"CJ Hoffmann","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0234937.ref014","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/tmi.12237","article-title":"Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study","volume":"19","author":"CJ Hoffmann","year":"2014","journal-title":"Trop Med Int Health"},{"issue":"17","key":"pone.0234937.ref015","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1097\/QAD.0b013e328311d16f","article-title":"Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen","volume":"22","author":"Z Fox","year":"2008","journal-title":"Aids"},{"issue":"1","key":"pone.0234937.ref016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09500340600677872","article-title":"Establishing a workplace antiretroviral therapy programme in South Africa","volume":"19","author":"S Charalambous","year":"2007","journal-title":"AIDS care"},{"issue":"2","key":"pone.0234937.ref017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/tmi.12639","article-title":"CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone","volume":"21","author":"CJ Hoffmann","year":"2016","journal-title":"Trop Med Int Health"},{"issue":"2","key":"pone.0234937.ref018","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.04215-14","article-title":"Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors","volume":"59","author":"AE Basson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pone.0234937.ref019","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"TF Liu","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"18","key":"pone.0234937.ref020","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1128\/JVI.02356-08","article-title":"Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1","volume":"83","author":"CM Parry","year":"2009","journal-title":"J Virol"},{"issue":"4","key":"pone.0234937.ref021","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1128\/AAC.01197-10","article-title":"Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1","volume":"55","author":"AL McCormick","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0234937.ref022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","volume":"10","author":"RE Barth","year":"2010","journal-title":"The Lancet Infectious diseases"},{"issue":"2","key":"pone.0234937.ref023","doi-asserted-by":"crossref","first-page":"ofv158","DOI":"10.1093\/ofid\/ofv158","article-title":"Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes","volume":"3","author":"A Huang","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"pone.0234937.ref024","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/jac\/dki042","article-title":"Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven","volume":"55","author":"GM Lucas","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"pone.0234937.ref025","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/aid.2017.0134","article-title":"Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps","volume":"33","author":"RA Murphy","year":"2017","journal-title":"AIDS research and human retroviruses"},{"issue":"14","key":"pone.0234937.ref026","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0000000000000349","article-title":"Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa","volume":"28","author":"ML Petersen","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"pone.0234937.ref027","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1186\/s12879-017-2680-6","article-title":"Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda","volume":"17","author":"V Ssempijja","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"5","key":"pone.0234937.ref028","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jac\/dkh162","article-title":"Paradoxes of adherence and drug resistance to HIV antiretroviral therapy","volume":"53","author":"DR Bangsberg","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"pone.0234937.ref029","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"DI Rosenbloom","year":"2012","journal-title":"Nature medicine"},{"issue":"5","key":"pone.0234937.ref030","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/00126334-200412150-00009","article-title":"Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation","volume":"37","author":"JJ Eron","year":"2004","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"issue":"Suppl 3","key":"pone.0234937.ref031","first-page":"85","article-title":"Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials","volume":"11","author":"MA Wainberg","year":"1997","journal-title":"Leukemia"},{"issue":"Suppl 5","key":"pone.0234937.ref032","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00002030-199612005-00002","article-title":"Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase","volume":"10","author":"MA Wainberg","year":"1996","journal-title":"Aids"},{"issue":"2 Suppl 1","key":"pone.0234937.ref033","first-page":"31","article-title":"Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients","volume":"27","author":"D Turner","year":"2004","journal-title":"The new microbiologica"},{"issue":"10","key":"pone.0234937.ref034","doi-asserted-by":"crossref","first-page":"e77691","DOI":"10.1371\/journal.pone.0077691","article-title":"Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study","volume":"8","author":"V von Wyl","year":"2013","journal-title":"PloS one"},{"issue":"11","key":"pone.0234937.ref035","doi-asserted-by":"crossref","first-page":"e25415","DOI":"10.1002\/jia2.25415","article-title":"HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis","volume":"22","author":"N Ford","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"pone.0234937.ref036","doi-asserted-by":"crossref","first-page":"100231","DOI":"10.1016\/j.eclinm.2019.12.001","article-title":"Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa","volume":"18","author":"G Villa","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"12","key":"pone.0234937.ref037","doi-asserted-by":"crossref","first-page":"e0167852","DOI":"10.1371\/journal.pone.0167852","article-title":"Might ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?","volume":"11","author":"R Rhead","year":"2016","journal-title":"PloS one"},{"issue":"2","key":"pone.0234937.ref038","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1386-6532(03)00033-7","article-title":"Therapeutic drug monitoring in the treatment of HIV-infection","volume":"27","author":"JG Gerber","year":"2003","journal-title":"J Clin Virol"},{"issue":"3","key":"pone.0234937.ref039","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FTD.0b013e31821b42d1","article-title":"The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection","volume":"33","author":"E Pretorius","year":"2011","journal-title":"Ther Drug Monit"},{"key":"pone.0234937.ref040","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3389\/fphar.2017.00831","article-title":"Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment-Clinical Points of View and Practical Considerations","volume":"8","author":"SA Iacob","year":"2017","journal-title":"Front Pharmacol"},{"issue":"11","key":"pone.0234937.ref041","doi-asserted-by":"crossref","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis","volume":"13","author":"Z Shubber","year":"2016","journal-title":"PLoS medicine"},{"issue":"12","key":"pone.0234937.ref042","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/tmi.13152","article-title":"Effectiveness of interventions for unstable patients on antiretroviral therapy in South Africa: results of a cluster-randomised evaluation","volume":"23","author":"MP Fox","year":"2018","journal-title":"Trop Med Int Health"},{"issue":"1","key":"pone.0234937.ref043","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2352-3018(16)30206-5","article-title":"Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis","volume":"4","author":"S Kanters","year":"2017","journal-title":"The lancet HIV"},{"issue":"1","key":"pone.0234937.ref044","doi-asserted-by":"crossref","first-page":"21371","DOI":"10.7448\/IAS.20.1.21371","article-title":"Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations","volume":"20","author":"JE Haberer","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"pone.0234937.ref045","article-title":"Barriers to HIV Medication Adherence as a Function of Regimen Simplification","author":"Y Chen","year":"2016","journal-title":"Annals of behavioral medicine: a publication of the Society of Behavioral Medicine"},{"issue":"11","key":"pone.0234937.ref046","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.JAA.0000502870.89587.b6","article-title":"What is the effect of pill burden on adherence to HIV antiretroviral therapy?","volume":"29","author":"SS Sutton","year":"2016","journal-title":"JAAPA: official journal of the American Academy of Physician Assistants"},{"issue":"11","key":"pone.0234937.ref047","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s10461-016-1287-z","article-title":"The Acceptability and Perceived Usefulness of a Weekly Clinical SMS Program to Promote HIV Antiretroviral Medication Adherence in KwaZulu-Natal, South Africa","volume":"20","author":"N Georgette","year":"2016","journal-title":"AIDS and behavior"},{"issue":"6","key":"pone.0234937.ref048","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11904-016-0335-7","article-title":"Community-Based ART Programs: Sustaining Adherence and Follow-up","volume":"13","author":"JS Mukherjee","year":"2016","journal-title":"Current HIV\/AIDS reports"},{"issue":"5","key":"pone.0234937.ref049","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11904-016-0325-9","article-title":"Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets","volume":"13","author":"JB Nachega","year":"2016","journal-title":"Current HIV\/AIDS reports"},{"issue":"2","key":"pone.0234937.ref050","doi-asserted-by":"crossref","first-page":"e0116144","DOI":"10.1371\/journal.pone.0116144","article-title":"Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland","volume":"10","author":"K Jobanputra","year":"2015","journal-title":"PloS one"},{"issue":"2","key":"pone.0234937.ref051","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/QAI.0000000000001479","article-title":"Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure","volume":"76","author":"SM McCluskey","year":"2017","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"issue":"12","key":"pone.0234937.ref052","doi-asserted-by":"crossref","first-page":"e0145772","DOI":"10.1371\/journal.pone.0145772","article-title":"HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing","volume":"10","author":"SY Rhee","year":"2015","journal-title":"PloS one"},{"key":"pone.0234937.ref053","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12879-016-1611-2","article-title":"Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm","volume":"16","author":"SE Rutstein","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"2","key":"pone.0234937.ref054","doi-asserted-by":"crossref","first-page":"e0118145","DOI":"10.1371\/journal.pone.0118145","article-title":"High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa","volume":"10","author":"L Skhosana","year":"2015","journal-title":"PloS one"},{"issue":"5","key":"pone.0234937.ref055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"G TenoRes Study","year":"2016","journal-title":"The Lancet Infectious diseases"},{"issue":"12","key":"pone.0234937.ref056","first-page":"3460","article-title":"Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART","volume":"73","author":"F Ceccherini-Silberstein","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pone.0234937.ref057","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/cid\/ciz214","article-title":"Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts >\/ = 500 Cells\/microL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa","volume":"70","author":"G Fatti","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:30:06Z","timestamp":1616286606000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234937"}},"subtitle":[],"editor":[{"given":"Cristian","family":"Apetrei","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0234937","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]}}}